Page 1,915«..1020..1,9141,9151,9161,917..1,9201,930..»

iShares Nasdaq Biotechnology Index (ETF) (IBB) Is at a Crossroads – Investorplace.com

Posted: Published on March 7th, 2017

By Serge Berger, Head Trader & Strategist, The Steady Trader|Mar 7, 2017, 8:02 am EST Popular Posts: Recent Posts: Biotechnology stocks as represented by theiShares Nasdaq Biotechnology Index (ETF)(NASDAQ:IBB) have rallied 13% year-to-date. Thats notable considering that over the past 12 months, the IBB ETF has only rallied by about 14%. Many traders in recent days have pointed to the continued strength in biotech stocks as a sign that the broader market is not yet ready to roll over. But it is notable that the IBB, as a result of the recent rally, has now reached an important technical level on the charts that may offer better technical resistance. A simple yet effective trick that I repeatedly use to gauge the internal strength of the broader stock market is by checking the pulse of the so calledrisk-on groups. While these groups change over the years, they often include technology and financial stocks. In recent years, biotech, tech as a whole and small-cap stocks, among others, have led the risk-on pack. Over the past few weeks, biotech stocks and the IBB ETF have showed both absolute and relative strength versus the broader stock market. Through this lens, one could argue that … Continue reading →

Posted in Biotechnology | Comments Off on iShares Nasdaq Biotechnology Index (ETF) (IBB) Is at a Crossroads – Investorplace.com

RBC Capital Markets Cuts Puma Biotechnology Inc (PBYI) Price Target to $17.00 – The Cerbat Gem

Posted: Published on March 7th, 2017

Benzinga RBC Capital Markets Cuts Puma Biotechnology Inc (PBYI) Price Target to $17.00 The Cerbat Gem Puma Biotechnology Inc logo Puma Biotechnology Inc (NYSE:PBYI) had its target price reduced by RBC Capital Markets from $48.00 to $17.00 in a research note issued to investors on Thursday morning. They currently have a sector perform rating on the ... The Puma Biotechnology Inc (PBYI) Price Target Cut to $17.00 by Analysts at RBC Capital MarketsDailyQuint Puma Biotechnology Shares Plunge On Plans To Modify Neratinib European MAA, Competitor Roche's Perjeta WinBenzinga Puma Biotechnology Inc Realized Volatility Hits A Notable HighCML News Smarter Analyst -Yahoo Finance -Sports Perspectives all 94 news articles » Go here to read the rest: RBC Capital Markets Cuts Puma Biotechnology Inc (PBYI) Price Target to $17.00 - The Cerbat Gem … Continue reading →

Posted in Biotechnology | Comments Off on RBC Capital Markets Cuts Puma Biotechnology Inc (PBYI) Price Target to $17.00 – The Cerbat Gem

Three New Tarantula Species Discovered in South America – Sci-News.com

Posted: Published on March 7th, 2017

Brazilian taxonomists have discovered and described three new species of the bird-eating tarantula genus Avicularia from Ecuador, Peru and Brazil. Avicularia merianae, female. Image credit: H.-W. Auer. The description is published in a new issue of the journal ZooKeys, authored by Dr. Caroline Sayuri Fukushima and Dr. Rogrio Bertani, researchers in the Laboratory of Ecology and Evolution at the Instituto Butantan in So Paulo, Brazil. Even though these harmless tarantulas have long been a favorite exotic pet around the world, their identity has remained problematic ever since the first species, the pinktoe tarantula (Aranea avicularia), was described back in 1758 by the father of modern taxonomy, Carl Linnaeus (1707-1778), the scientists explained. He described the species based on a hodgepodge of spiders. Over the next centuries, other species with completely different characteristics were called Avicularia creating a huge mess. As a result, basic questions, such as the characteristic traits of the genus, the number of its species and their localities, have been left unanswered. To address the confusion, Dr. Fukushima and Dr. Bertani studied both newly collected specimens and also specimens from museum collections. The authors concluded that, instead of the 49 species previously assigned to the genus Avicularia, there … Continue reading →

Posted in Biology | Comments Off on Three New Tarantula Species Discovered in South America – Sci-News.com

Student profile: Keegan Mendez – Harvard School of Engineering and Applied Sciences

Posted: Published on March 7th, 2017

This sky-diving, squash-playing, thrill-seeking student is gearing up for her next great adventurein biomedical engineering research and discovery. Why did you decide to concentrate in biomedical engineering? As a child, I always had a love of math and science, and I liked to use my hands to create thingsI shunned Barbie dolls for building blocks. I was already a math and science nerd, but what appealed to me about bioengineering specifically is the breadth and diversity of research options, from organs on a chip to medical device design, and everything in between. The research that is happening right nowlike trying to grow a human heart outside the bodyis so cutting-edge and exciting. Tell us about some of the bioengineering research youve had the opportunity to conduct at SEAS. During my sophomore year, I began working in David Mooneys lab on developing the TheraCardium, which is a cardiac device for stem cell delivery to the heart for patients who have suffered a heart attack. The device supports regrowth of the damaged tissue and helps to prevent scarring of the dead heart muscle, in an effort to help prevent future cardiac events. Mendez works on a biomedical research project in the Mooney … Continue reading →

Posted in BioEngineering | Comments Off on Student profile: Keegan Mendez – Harvard School of Engineering and Applied Sciences

Sanofi, Regeneron post more positive dupilumab data as PDUFA date for eczema blockbuster-in-waiting nears – FierceBiotech

Posted: Published on March 7th, 2017

Sanofi and Regeneron have taken a deeper dive into phase 3 data on hotly tipped atopic dermatitis drug dupilumab. The fresh results further burnish the credentials of an asset that is up for review at FDA this month. Dupilumab, which will be sold under the brand name Dupixent if it wins approval, has aced a series of tests over the past year. The latest analysis, which looks at one of three phase 3 studies of the IL-4 and IL-13 inhibiting antibody, continues the winning streak. Dupilumab comfortably beat the placebo against a range of secondary endpoints, regardless of whether the analysis was run after 16 or 52 weeks of treatment. Having revealed in June that the CHRONOS trial met its primary endpoint of skin lesion clearances after 16 weeks and cleared some key secondary goals, Sanofi and Regeneron have followed up with data on other measurements. The trial linked both dupilumab regimenswhich gavethe experimental drug with topical corticosteroidsto statistically significant improvements on the Pruritus Numerical Rating Scale, Patient Oriented Eczema Measure and Dermatology Life Quality Index at 16 and 52 weeks. The proportion of patients whose condition improved against these scales at 16 and 52 weeks were comparable, adding to … Continue reading →

Posted in Eczema | Comments Off on Sanofi, Regeneron post more positive dupilumab data as PDUFA date for eczema blockbuster-in-waiting nears – FierceBiotech

Intramuscular Flu Vaccination Recommended for Patients With Eczema – Infectious Disease Advisor (registration)

Posted: Published on March 7th, 2017

Infectious Disease Advisor (registration) Intramuscular Flu Vaccination Recommended for Patients With Eczema Infectious Disease Advisor (registration) Intramuscular rather than intradermal flu vaccination is preferred in patients with S aureus colonized atopic dermatitis. HealthDay News For patients with moderate/severe atopic dermatitis (AD), those colonized with Staphylococcus aureus have a ... Continue reading here: Intramuscular Flu Vaccination Recommended for Patients With Eczema - Infectious Disease Advisor (registration) … Continue reading →

Posted in Eczema | Comments Off on Intramuscular Flu Vaccination Recommended for Patients With Eczema – Infectious Disease Advisor (registration)

Dating with Ulcerative Colitis – EmpowHer

Posted: Published on March 7th, 2017

Managing a First Date with Ulcerative Colitis Let's face it: First dates can be tough. Add in the bloating, stomach pain, and sudden bouts of bleeding and diarrhea that come with ulcerative colitis (UC), and it's enough to make you want to forget the hottie next door and stay home. On top of dealing with embarrassing symptoms, UC often hits in the midst of the dating years. Most people are diagnosed between the ages of 15 and 30. But just because you have UC doesn't mean you can't enjoy time with friends or give romance a chance. Try these tips from people who've been there. Pick a place you know well, or scout out the bathroom situation ahead of time if you're going someplace new. Dinner and a movie is usually a safe bet, but avoid crowded bars where there may be long lines for the restrooms. You may want to forgo an afternoon of hiking, biking, or kayaking for a museum or theme park instead. Do what you can to ease the jitters, especially if stress or nerves seem to make your symptoms worse. Wear something you feel good and confident in, and give yourself plenty of time to … Continue reading →

Posted in Ulcerative Colitis | Comments Off on Dating with Ulcerative Colitis – EmpowHer

Renown Pharma Announces Successful Results of Apomorphine Sub-Lingual Spray Pharmacokinetic Study to Treat … – PR Newswire (press release)

Posted: Published on March 7th, 2017

LONDON, March 7, 2017 /PRNewswire/ -- Renown Pharma Limited ("Renown") today announced the results of a pharmacokinetic study intended to compare the plasma concentrations of Renown's sub-lingual apomorphine spray against the currently approved formulation of injectable apomorphine used to treat motor fluctuations, or "OFF" episodes, in Parkinson's disease patients. The pharmacokinetics and safety/tolerability of Renown's sub-lingual apomorphine spray were demonstrated in a Phase I pilot study in 12 healthy volunteers with all subjects receiving a 2.5mg sub-cutaneous injection of apomorphine on day 1 followed by escalating 10, 15, 20 & 25mg doses of sub-lingual apomorphine spray on the subsequent four days. The 25mg apomorphine spray dose closely replicated the characteristics of the sub-cutaneous injectable with very fast absorption (peak plasma concentration at 15-20 minutes) and similar peak plasma concentrations. Based on these data, the estimated time to "ON" in patients with Parkinson's disease is expected to be 5-10 minutes which is similar to the injectable. Renown believes that the therapeutic dose for the sub-lingual apomorphine spray to treat "OFF" episodes in Parkinson's patients will be in the range of 15mg-25mg for the majority of patients. Dr. Anthony Clarke, Chief Scientific Officer of Renown, commented, "Patients report that "OFF" episodes in … Continue reading →

Posted in Parkinson's Treatment | Comments Off on Renown Pharma Announces Successful Results of Apomorphine Sub-Lingual Spray Pharmacokinetic Study to Treat … – PR Newswire (press release)

Disabled veteran announces candidacy for Lichtenegger’s term-limited seat in 2018 – Southeast Missourian

Posted: Published on March 7th, 2017

Editor's note: the following story has been edited to clarify a statement regarding how the incumbent representative reacted to LaForest's plans to run for office. Tony LaForest, 51, of Jackson announced his candidacy Thursday for state representative in District 146 as a Republican, and the issues that mean the most to him are concerns of personal relevance. LaForest said he had been in contact with state Rep. Donna Lichtenegger about running for her seat after she reached her term limit in 2018. LaForest said Lichtenebber was "very happy with it." LaForest served 11 years in the Marine Corps, first as a military police officer and then as infantry. His spine was crushed during the Gulf War in 1991, and he is a 100 percent disabled veteran with degenerative joint disease. LaForest spent years working through Veterans Affairs paperwork on his own case. Since 2014, he has helped other veterans try to get the care they need. A Korean war veteran believed LaForest saved his life, LaForest said. He said he encouraged the man to get treatment for an injury sustained during his service. A doctor ended up diagnosing the man with pancreatic cancer while treating him for the leg injury, … Continue reading →

Posted in Cerebral Palsy Treatment | Comments Off on Disabled veteran announces candidacy for Lichtenegger’s term-limited seat in 2018 – Southeast Missourian

Ask A Doctor: Raise brain injury awareness – Herald Times Reporter

Posted: Published on March 7th, 2017

Dr. Paul Baek, For USA TODAY NETWORK-Wisconsin Published 1:32 p.m. CT March 6, 2017 | Updated 17 hours ago Dr. Paul Baek(Photo: Provided) Question: How big a deal is Brain Injury Awareness Month? Answer: Its a big deal, because were not talking about it frequently enough. Brain injury is often referred to as a silent epidemic because few people know about it, despite the eye-opening number of people injured each year. RELATED:Ask A Doctor: Facts about multiple sclerosis SUBSCRIBE:Follow us today on YouTube More than 3.5 million people experience a brain injury each year, according to the Brain Injury Association of America. An estimated 12 million Americans live with the impact of such an injury. A brain injury can occur anytime our head is subjected to a strong bump, blow, jolt or penetrating injury that interrupts the normal function of the brain. Some brain injuries are traumatic, such as a head injury sustained during a car crash. Some are the result ofnon-traumatic causes like drowning, stroke or infection. Others are less severe, but may still cause disturbances in normal brain function, as experienced during a concussion. Creating awareness of brain injuries and how to prevent them is critical. Given that … Continue reading →

Posted in Brain Injury Treatment | Comments Off on Ask A Doctor: Raise brain injury awareness – Herald Times Reporter

Page 1,915«..1020..1,9141,9151,9161,917..1,9201,930..»